GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Probability of Financial Distress (%)

CUTR (Cutera) Probability of Financial Distress (%) : 5.69% (As of Dec. 14, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cutera Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Cutera's Probability of Financial Distress (%) is 5.69%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Cutera's Probability of Financial Distress (%)

For the Medical Devices subindustry, Cutera's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutera's Probability of Financial Distress (%) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cutera's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Cutera's Probability of Financial Distress (%) falls into.



Cutera Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-2.81

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=5.69%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Cutera  (NAS:CUTR) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Cutera Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Cutera's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutera Business Description

Industry
Traded in Other Exchanges
Address
3240 Bayshore Boulevard, Brisbane, CA, USA, 94005
Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.
Executives
Michael Karavitis officer: EVP, Chief Technology Officer C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Taylor C. Harris director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond officer: Interim Chief Financial Office C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones officer: Chief Operating Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry director, officer: Chief Executive Officer 9775 TOLEDO, IRVINE CA 92618
Rohan Seth officer: Chief Financial Officer C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann director 1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants director ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters director